Nasus Pharma announces results from Phase 2 study of NS002

Nasus Pharma (NSRX) announced positive interim results from its Phase 2 clinical study of NS002, the Company’s investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. The data demonstrated that NS002 achieved faster absorption, higher peak concentrations, and greater early epinephrine exposure compared to intramuscular EpiPen autoinjector. NS002 demonstrated a higher mean peak plasma concentration of 655 pg/ml compared to 548 pg/ml for EpiPen, and achieved peak concentration in 10.8 minutes compared to 15 minutes with EpiPen. 91% of participants administered NS002 reached the epinephrine plasma threshold of 100 pg/ml at 5 minutes, compared to 67% of those administered EpiPen. Total epinephrine absorption in the 10 minute period following administration-the critical window for resolving anaphylaxis-was higher in participants administered NS002 compared to EpiPen.